Voya Investment Management LLC grew its stake in Otonomy, Inc. (NASDAQ:OTIC) by 17.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,606 shares of the biopharmaceutical company’s stock after purchasing an additional 1,918 shares during the quarter. Voya Investment Management LLC’s holdings in Otonomy were worth $238,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. TD Asset Management Inc. acquired a new position in shares of Otonomy in the 2nd quarter valued at $624,000. Dimensional Fund Advisors LP lifted its stake in shares of Otonomy by 47.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 311,169 shares of the biopharmaceutical company’s stock valued at $3,812,000 after purchasing an additional 100,059 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Otonomy by 6.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 114,786 shares of the biopharmaceutical company’s stock valued at $1,407,000 after purchasing an additional 6,798 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Otonomy by 10,065.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 517,410 shares of the biopharmaceutical company’s stock valued at $9,753,000 after purchasing an additional 512,320 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of Otonomy by 8.7% in the 2nd quarter. Alliancebernstein L.P. now owns 672,876 shares of the biopharmaceutical company’s stock valued at $12,684,000 after purchasing an additional 54,080 shares during the period. 78.12% of the stock is currently owned by institutional investors.

OTIC has been the topic of a number of analyst reports. BidaskClub downgraded Otonomy from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies downgraded Otonomy from an “overweight” rating to a “neutral” rating and cut their price target for the company from $32.00 to $8.00 in a research note on Wednesday, August 30th. J P Morgan Chase & Co raised Otonomy from a “neutral” rating to an “overweight” rating and set a $28.00 price target on the stock in a research note on Tuesday, August 15th. Cowen and Company reissued an “outperform” rating and issued a $9.00 price target (down previously from $55.00) on shares of Otonomy in a research note on Thursday, August 31st. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $15.00 price objective (down previously from $45.00) on shares of Otonomy in a research report on Thursday, August 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $9.15.

Shares of Otonomy, Inc. (NASDAQ:OTIC) opened at $5.55 on Friday. Otonomy, Inc. has a 1 year low of $2.80 and a 1 year high of $21.15.

Otonomy (NASDAQ:OTIC) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.15. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. The business had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.43 million. The company’s quarterly revenue was down 12.8% on a year-over-year basis. analysts expect that Otonomy, Inc. will post -2.88 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Voya Investment Management LLC Has $238,000 Stake in Otonomy, Inc. (OTIC)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/19/voya-investment-management-llc-has-238000-stake-in-otonomy-inc-otic.html.

About Otonomy

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Want to see what other hedge funds are holding OTIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Otonomy, Inc. (NASDAQ:OTIC).

Institutional Ownership by Quarter for Otonomy (NASDAQ:OTIC)

Receive News & Stock Ratings for Otonomy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy Inc. and related stocks with our FREE daily email newsletter.